Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

David Kleinman

Endocrinology, Diabetes & Metabolism Toms River, NJ Medical Doctor

NPI 1639123755 CMS profile 209471

40 Bey Lea Rd Ste B202, Toms River, NJ 08753

Open in the dashboard

General payments

$2,278

113 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, David Kleinman of Toms River, NJ is reported in the CMS Open Payments database as having received $2,278 across 113 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $894 45
2020 General $413 25
2019 General $970 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Kleinman
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to David Kleinman were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year David Kleinman Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $970 $494 $123–$2,253 $163
2020 $413 $335 $85–$1,841 $114
2021 $894 $398 $88–$1,981 $132
2022 $0 $364 $88–$1,568 $149
2023 $0 $420 $113–$1,614 $160
2024 $0 $440 $121–$1,646 $164
2025 $0 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. AstraZeneca Pharmaceuticals LP $554 25 payments
  2. Novo Nordisk Inc $551 15 payments
  3. Amneal Pharmaceuticals LLC $300 30 payments
  4. Lilly USA, LLC $212 11 payments
  5. Abbott Laboratories $157 8 payments
  6. Sanofi-Aventis U.S. LLC $110 3 payments
  7. AbbVie, Inc. $91 1 payment
  8. Xeris Pharmaceuticals, Inc. $59 4 payments
  9. Dexcom, Inc. $44 3 payments
  10. Shire North American Group Inc $41 3 payments
  11. Other $157 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $2,278 113 payments
Products named General payments · program years 2019–2021
  1. FARXIGA $529 24 payments
  2. Ozempic $426 14 payments
  3. UNITHROID $300 30 payments
  4. RYBELSUS $254 10 payments
  5. BAQSIMI $107 8 payments
  6. TRULICITY $95 2 payments
  7. SOLIQUA 100/33 $83 1 payment
  8. FreeStyle Libre Pro $79 4 payments
  9. GVOKE PFS $59 4 payments
  10. FreeStyle Libre 2 $58 3 payments
  11. Other $365 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

113 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record